Get the Stockscreener App
30.28
4.66%
-1.48
After Hours:
30.28
Forte Biosciences Inc stock is traded at $30.28, with a volume of 151.39K.
It is down -4.66% in the last 24 hours and up +5.10% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$31.76
Open:
$31.58
24h Volume:
151.39K
Relative Volume:
0.78
Market Cap:
$379.32M
Revenue:
-
Net Income/Loss:
$-51.74M
P/E Ratio:
-6.8135
EPS:
-4.4441
Net Cash Flow:
$-44.57M
1W Performance:
+3.49%
1M Performance:
+5.10%
6M Performance:
+168.92%
1Y Performance:
+341.40%
1-Day Range:
$30.25
$32.97
1-Week Range:
$28.25
$32.97
52-Week Range:
$4.90
$35.62
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
30.28 | 397.86M | 0 | -51.74M | -44.57M | -4.4441 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Stock Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules - The Joplin Globe
Biotech Forte Biosciences hands 100,000 stock options to new hires - Stock Titan
Celiac Disease Market: Expanding Revenue Landscape to 2034 – DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer - StreetInsider
(FBRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
FBRX PE Ratio & Valuation, Is FBRX Overvalued - Intellectia AI
Forte Biosciences (FBRX) Raised to Buy: Key Information You Need - Bitget
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Pullback Watch: Is Forte Biosciences Inc a top pick in the sector2025 Risk Factors & Low Volatility Stock Suggestions - baoquankhu1.vn
Is Forte Biosciences Inc. a top pick in the sectorWeekly Stock Summary & Weekly Watchlist for Hot Stocks - mfd.ru
Will Forte Biosciences Inc. benefit from rate cutsQuarterly Portfolio Report & Stepwise Swing Trade Plans - mfd.ru
Price-Driven Insight from (FBRX) for Rule-Based Strategy - Stock Traders Daily
Stock Traders Purchase Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Analyst Downgrade: Is Forte Biosciences Inc stock a good dividend stockCEO Change & Growth Focused Entry Reports - baoquankhu1.vn
We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth - Yahoo Finance
Celiac Disease Clinical Trial Pipeline Gains Momentum as 25+ - openPR.com
Growth Recap: How much upside does KWESST Micro Systems Inc Equity Warrant havePortfolio Performance Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Why Forte Biosciences Inc. stock is popular among millennialsJuly 2025 Reactions & Daily Profit Maximizing Tips - mfd.ru
Forte Biosciences, Inc. (NASDAQ:FBRX) Sees Large Decrease in Short Interest - MarketBeat
Why Airbnb Inc. stock is favored by top institutionsJuly 2025 Institutional & Reliable Price Breakout Alerts - mfd.ru
Celiac Disease Clinical Trial Pipeline Gains Momentum As 25+ Companies Advance Novel Therapies Toward Market Entry: Delveinsight Teva Pharmaceutical Industries, Barinthus Biotherapeutics, Topas - Menafn.com
Janus Henderson discloses 11.4% Forte Biosciences (FBRX) ownership stake - Stock Titan
Will Forte Biosciences Inc. stock deliver better than expected guidanceQuarterly Earnings Report & Proven Capital Preservation Tips - mfd.ru
Is Forte Biosciences Inc. stock a good choice for value investors2025 Technical Patterns & AI Forecast for Swing Trade Picks - mfd.ru
Can Forte Biosciences Inc. maintain its current growth rateDollar Strength & AI Powered Buy/Sell Recommendations - mfd.ru
Institutional Owners May Ignore Forte Biosciences, Inc.'s (NASDAQ:FBRX) Recent US$87m Market Cap Decline as Longer-term Profits Stay in the Green - 富途牛牛
Does Forte Biosciences Inc. have pricing powerPortfolio Performance Summary & Growth Focused Stock Pick Reports - mfd.ru
Layoff Watch: Is Forte Biosciences Inc being accumulated by smart moneyJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings - marketscreener.com
Forte Biosciences chief lines up Guggenheim, TD Cowen, Barclays talks - Stock Titan
Forte Biosciences Insider Ups Holding By 30% During Year - simplywall.st
Aug Outlook: Will BEAM stock recover after earningsWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
(FBRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Dow Update: Will Forte Biosciences Inc announce a stock splitWeekly Trading Summary & Weekly Momentum Picks - baoquankhu1.vn
Short Interest in Forte Biosciences, Inc. (NASDAQ:FBRX) Expands By 55.5% - MarketBeat
Federated Hermes Inc. Acquires 563,147 Shares of Forte Biosciences, Inc. $FBRX - MarketBeat
Celiac Disease Pipeline 2025: FDA Updates, Therapy - openPR.com
(FBRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Celiac Disease Clinical Trial Pipeline Gains Momentum: 25+ - openPR.com
Trend Recap: Can META stock outperform in a bear marketTrade Volume Summary & AI Forecast Swing Trade Picks - baoquankhu1.vn
US Market Recap: What is the earnings history of Jupiter Neurosciences Inc2025 Stock Rankings & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
CD122’s double whammy makes for intriguing target - BioWorld MedTech
Is Forte Biosciences Inc. stock oversold or undervaluedJuly 2025 Sector Moves & Real-Time Volume Triggers - Bollywood Helpline
Is Forte Biosciences Inc a top pick in the sectorWeekly Trade Review & Expert Verified Movement Alerts - baoquankhu1.vn
Support Test: How does INVE compare to its peersQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn
Layoff Watch: Is ERAS stock undervalued right nowMarket Performance Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Value Recap: Does Forte Biosciences Inc have pricing powerPortfolio Gains Report & Daily Growth Stock Tips - baoquankhu1.vn
Trade Recap: Is Forte Biosciences Inc. stock a hidden gemWeekly Gains Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '26 |
Option Exercise |
0.00 |
375 |
0 |
41,895 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Dec 30 '25 |
Buy |
26.33 |
9,680 |
254,833 |
41,520 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,974 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,733 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,372 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):